Regeneron Pharmaceuticals - 53 Year Dividend History | REGN

Historical dividend payout and yield for Regeneron Pharmaceuticals (REGN) since 1971. The current TTM dividend payout for Regeneron Pharmaceuticals (REGN) as of May 24, 2024 is $0.00. The current dividend yield for Regeneron Pharmaceuticals as of May 24, 2024 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $108.045B $13.117B
Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also developed an antibody cocktail for COVID-19, REGEN-COV. REGEN-COV is a cocktail of two monoclonal antibodies and was designed specifically to block the infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron has a collaboration agreement with Roche for the same. While Regeneron has co-developed Eylea with Bayer's HealthCare unit, Praluent was co-developed with Sanofi. Regeneron collaborated with Bayer for the joint development and commercialization of co-formulated combinations of Eylea, rinucumab and nesvacumab for the treatment of ocular diseases or disorders outside the United States.
Stock Name Country Market Cap PE Ratio